The amylin that hit incretin-level weight loss — and rewrote the class's market lesson. Eloralintide (Lilly) closes the register's amylin lineage on a high note, and it comes with a genuinely beautiful backstory. Three threads: (1) the amylin origin story — the whole class descends from a mysterious
Eloralintide (Lilly's LY3841136) is a once-weekly, selective amylin-receptor agonist — and it closes the register's amylin story with the class's strongest monotherapy data yet. The amylin lineage has a lovely origin: the hormone was discovered as the mysterious amyloid "junk" clogging diabetics' pancreases for a century, which turned out to be a third islet hormone that signals fullness (co-secreted with insulin). Eloralintide's Phase 2 (Lancet, 2025) delivered up to ~20% mean weight loss over 48 weeks (range 9.5–20.1% vs 0.4% placebo) — incretin-class numbers from a non-incretin mechanism — with generally good tolerability (GI/fatigue AEs dose-dependent; placebo-like at lower doses). That result matters beyond the drug: arriving just after Petrelintide (#69) — whose ~10.7% disappointed the market — eloralintide shows the amylin class can reach the top tier, so efficacy magnitude, not just tolerability, is the real battleground. Lilly went straight to Phase 3 and is testing an eloralintide + tirzepatide combination. The honest read: a standout Phase 2 for a selective amylin agonist — high efficacy, good tolerability — but still investigational, Phase 3 pending, and (as Petrelintide showed) mid-stage promise isn't approval.
investigational; not approved. Phase 2 complete → Phase 3 enrolling (obesity). A well-capitalized Lilly clinical program, not a gray-market compound.
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026 (Phase 3 obesity enrolling; eloralintide + tirzepatide combination and Phase 3 readouts are the catalysts — and the real test of whether ~20% holds at scale).
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.